Pharmacokinetics and pharmacodynamics of antibiotics in otitis media

Pediatric Infectious Disease Journal

Volumn 15, Issue 3, 1996, Pages 255-259

  Craig, William A ^a,b   Andes, David ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

middle ear fluid; Otitis media; pharmacodynamics; pharmacokinetics

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFTRIAXONE; CEFUROXIME; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LORACARBEF; MACROLIDE;

DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG PENETRATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; OTITIS MEDIA; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; OTITIS MEDIA; PENICILLIN RESISTANCE; PHARMACOKINETICS; STREPTOCOCCUS PNEUMONIAE;

EID: 0029988372     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199603000-00015     Document Type: Review

References (30)

1. Redington J, Ebert S, Craig WA. Role of antimicrobial pharmacokinetics and pharmacodynamics in surgical prophylaxis. Rev Infect Dis 1991;13:S790-9.
2. Barr WH, Affrime M, Lin CC, Batra V. Pharmacokinetics of ceftibuten in children. Pediatr Infect Dis J 1995;14:S93-101.
3. Shyu WC, Haddad J, Reilly J, Khan WN, Campbell DA, Tsai Y, Barbhaiya RH. Penetration of cefprozil into middle ear fluid of patients with otitis media. Antimicrob Agents Chemother 1994;38:2210-12.
4. Krause PJ, Owens NJ, Nightingale CH, Klimek JJ, Lehmann WB, Quintiliani R. Penetration of amoxicillin, cefaclor, erythromycin-sulfisoxazole, and trimethoprim-sulfamethoxazole into the middle ear fluid of patients with chronic serous otitis media. J Infect Dis 1982;145:815-21.
5. Klimek JJ, Nightingale C, Lehmann WB, Quintiliani R. Comparison of concentrations of amoxicillin and ampicillin in serum and middle ear fluid of children with chronic otitis media. J Infect Dis 1977;135:999-1002.
6. Eden T, Anari M, Ernstson S, Sundberg L. Penetration of cefaclor to adenoid tissue and middle ear fluid in secretory otitis media. Scand J Infect Dis 1983;39(Suppl.):48-52.
7. Harrison CJ, Chartrand SA, Rodriguez W, et al. Middle ear fluid (MEF) concentrations of cefixime (Cfxm) in acute otitis media (AOM) and otitis media with effusion (OME) Presented at the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October, 1994.
8. Kafetzis DA, Carabines C, Bairamis T, Apostolopoulos N. Diffusion of four oral cephalosporins into the middle ear exudate (MEE) of children suffering from acute otitis media (AOM) [Abstract 941]. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October, 1993.
9. Haddad J, Isaacson G, Respler DS, et al. Concentration of cefuroxime in serum and middle ear effusion after single dose treatment with cefuroxime axetil. Pediatr Infect Dis J 1991; 10:294-8.
10. Kusmiesz H, Shelton S, Brown O, Manning S, Nelson JD. Loracarhef concentrations in middle ear fluid. Antimicrob Agents Chemother 1990;34:2030-1.
11. Nelson CT, Mason EO, Kaplan SL. Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment. Pediatr Infect Dis J 1994;13:585-9.
12. Guay DKP, Craft JC. Overview of the pharmacology of clarithromycin suspension in children and a comparison with that in adults. Pediatr Infect Dis J 1993;12:S106-11.
13. Vogelman B, Gudmundsson S, Leggett J, Turnidle, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in animal model. J Infect Dis 1988;158:831-47.
14. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis 1991;74:S63-70.
15. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
16. Urban A, Andes D, Craig WA. In-vivo activity of cefpodoxime against penicillin-resistant pneumococci. Presented at the 19th International Congress of Chemotherapy, Montreal, Quebec, Canada, July, 1995.
17. Andes D, Urban A, Craig WA. In-vivo activity of amoxicillin and amoxicillin-clavulanate against penicillin-resistant pneumococci [Abstract A82]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September, 1995.
18. Craig WA. Post-antibiotic effect of macrolides. In: Macrolides. Paris: Arnette Blackwell, 1993:205-8.
19. Klein JO. Microbiologic efficacy of antibacterial drugs for acute otitis media. Pediatr Infect Dis J 1993;12:973-5.
20. Pukander JS, Jero JP, Kaprio EA, Sorri MJ. Clarithromycin vs. amoxicillin suspensions in the treatment of pediatric patients with acute otitis media. Pediatr Infect Dis J 1993; 12:S118-21.
21. Howie V. Eradication of bacterial pathogens from middle ear infections. Clin Infect Dis 1992;14:S209-11.
22. Howie VM, Dillard KRD, Lawrence B. In vivo sensitivity test in otitis media: efficacy of antibiotics. Pediatr 1985;75:8-13.
23. Dagan R, Abramson O, Leibovitz E, et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media (AOM) caused by intermediately penicillin-resistant pneumococci [Abstract LB-25]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September, 1995.
24. Jorgensen JH, Doern GV, Maher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzas, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 1990;34:2075-80.
25. Doern GV, Jorgensen JH, Thornsberry C, et al. National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae. Antimicrob Agents Chemother 1988;32:180-5.
26. Doern GV, Tubert TA. In vitro activities of 39 antimicrobial agents for Branhamella catarrhalis and comparison of results with different quantitative susceptibility test methods. Antimicrob Agents Chemother 1988;32:259-61.
27. Spangler SK, Jacobs MR, Appelbaum PC. In vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5555), a new oral penem, compared with those to penicillin G, amoxicillin, amoxicillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. Antimicrob Agents Chemother 1994;38:2902-4.
28. Doern GV, Vautour R, Parker D, Tubert T, Torres B. In vitro activity of loracarbef (LY163892), a new oral carbacephem antimicrobial agent, against respiratory isolates of Haemophilus influenzae and Moraxella catarrhalis. Antimicrob Agents Chemother 1991;35:1504-7.
29. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin. Antimicrob Agents Chemother 1992;36: 856-9.
30. Neu HC. Activity of macrohdes against common pathogens in vitro. In: Macrolides. Paris: Arnette Blackwell, 1993:167-82.